Pressmeddelanden & Nyheter

0
Rate this post
  • Nov 30, 2018 Governing news release: Boost in the number of shares and enact Hansa Medical abdominal (publ).
  • Nov 21, 2018 Hansa Medical presents at the Evercore ISI HealthConX Seminar.
  • Nov 14, 2018 Regulatory press release: Hansa Medical has actually finished a private placement of SEK 453 million/ USD 50 million.
  • Nov 13, 2018 Regulatory news release: Hansa Medical intends to perform a personal positioning of SEK 450 M/ USD 50.
  • Nov 09, 2018 Regulatory press release: Notification of Extraordinary General Meeting of Hansa Medical AB (publ).
  • Nov 01, 2018 Regulatory press release: Hansa Medical Interim Record July – September 2018.
  • Oct 31, 2018 Governing news release: Increase in the variety of shares and also enact Hansa Medical abdominal muscle (publ).
  • Oct 29, 2018 Regulative press release: Communiqué from the Phenomenal General Meeting of Hansa Medical abdominal (publ).
  • Oct 26, 2018 Regulative press release: Results presented at ASN Kidney Week 2018 highlight proceeded secure kidney feature for approximately 24 months after hair transplant.
  • Oct 25, 2018 Hansa Medical introduces nomination committee for the 2019 Annual General Meeting as well as economic schedule for 2019.
  • Oct 25, 2018 Hansa Medical releases the company’s interim report for the 3rd quarter of 2018 and invites to a teleconference and web presentation.
  • Oct 24, 2018 Governing news release: Hansa Medical gets positive point of view pertaining to orphan medicine status in the EU for imlifidase and therapy of anti-GBM condition.
  • Oct 17, 2018 Regulatory news release: Hansa Medical gets Fast Track standing for imlifidase in FDA transplant.
  • Oct 05, 2018 Governing press release: Notice of Amazing General Satisfying of Hansa Medical AB (publ).
  • Sep 27, 2018 Regulatory news release: Hansa Medical reports positive results from two stage 2 studies with imlifidase in kidney transplantation.
  • Sep 17, 2018 Regulative news release: Hansa Medical assigns Vincenza Nigro as Vice President, Global Medical Affairs.
  • Sep 06, 2018 Governing press release: Issue and repurchase of C shares for incentive programs.
  • Aug 06, 2018 Hansa Medical starts a follow-up study of people treated with the medication prospect imlifidase (IdeS) before kidney transplant.
  • Jul 31, 2018 Regulatory press release: Rise in the number of shares as well as enact HansaMedical abdominal (publ).
  • Jul 19, 2018 Governing news release: Hansa Medical Interim Record April – June 2018.
  • Jul 12, 2018 Regulatory press release: Hansa Medical invites to webcast telephone discussion of the company’s interim record for the second quarter of 2018.
  • Jul 09, 2018 Regulative press release: Hansa Medical’s medicine prospect imlifidase (IdeS) is provided Orphan Medicine Designation standing by the FDA for the treatment of anti-GBM condition.
  • Jun 29, 2018 Regulatory press release: Increase in the number of shares in Hansa Medical abdominal (publ).
  • Jun 15, 2018 The period for share subscription in Hansa Medical’s warrant program TO2015 has started.
  • Jun 06, 2018 Regulative press release: Presentation at the 2018 American Transplant Congress reveals the lasting threat/ benefit profile of imlifidase (IdeS) in kidney transplantation.
  • May 30, 2018 Governing news release: Follow-up results from trial-initiated Phase II research study with imlifidase (IdeS) will certainly be presented at the 2018 American Transplant Congress (ATC).
  • May 29, 2018 Regulative press release: Communiqué from the Yearly General Meeting of Hansa Medical abdominal muscle (publ).
  • Apr 25, 2018 Regulatory press release: Hansa Medical acting record January– March 2018.
  • Apr 25, 2018 Regulative news release: Notice of Yearly General Satisfying of Hansa Medical abdominal muscle (publ).
  • Apr 18, 2018 Hansa Medical invites to webcast telephone presentation of the firm’s interim report for the first quarter of 2018.
  • Apr 11, 2018 Regulatory press release: Hansa Medical publishes annual report for 2017.
  • Mar 21, 2018 Regulative press release: Arise from Hansa Medical’s first Phase II research with IdeS published by American Journal of Transplantation.
  • Mar 20, 2018 Regulative press release: Søren Tulstrup designated new President as well as chief executive officer of Hansa Medical.
  • Feb 16, 2018 Regulative news release: Hansa Medical gave orphan drug status for IdeS as well as therapy of Guillain-Barré syndrome in the USA.
  • Feb 14, 2018 Preliminary evaluation of a subpopulation in the Highdes research reveals excellent kidney function 5.5 months (average) after transplant.
  • Feb 14, 2018 Regulative news release: Hansa Medical Year-End Report 2017.
  • Feb 07, 2018 Hansa Medical welcomes to webcast telephone presentation of the company’s year-end record for 2017.
  • Jan 31, 2018 Regulatory press release: Rise in the number of votes in Hansa Medical abdominal muscle (publ).
  • Jan 04, 2018 Governing news release: Finished person employment for Hansa Medical’s international multicenter study Highdes.
  • Jan 03, 2018 Regulatory news release: Completed employment of individuals for United States Stage II research study with IdeS in highly sensitized individuals.

LÄMNA ETT SVAR

Vänligen ange din kommentar!
Vänligen ange ditt namn här